Published online Jan 6, 2024. doi: 10.12998/wjcc.v12.i1.68
Peer-review started: November 10, 2023
First decision: November 22, 2023
Revised: December 5, 2023
Accepted: December 18, 2023
Article in press: December 18, 2023
Published online: January 6, 2024
Processing time: 53 Days and 4.9 Hours
Recent studies on anticoagulation on dialysis in patients with renal failure suggest, Nafamostat mesylate, a broad-spectrum highly potent serine protease inhibitor with potent anticoagulation and antifibrous activity, with a significant anticoagulant effect.
In the early clinical stage of terminal renal failure, there are no obvious symptoms. With the progression of the disease, limb edema, fatigue, gastrointestinal bleeding and other symptoms gradually appear, and more serious and even consciousness disorders and cardiac arrest, seriously endangering the life of the patient.
Efficacy and safety of Nafamostat mesylate in patients with end-stage renal failure.
It was divided into observation group and control group. The clinical efficacy indicators of the two groups were compared.
While the number of patients in grade 0 was lower in the control group, and the number of patients in grades II and III was higher in the control group (P < 0.05). The post-treatment prothrombin time, activated partial thromboplastin time, thrombin time, and international normalized ratio values in the control group were higher than those in the observation group.
The use of Nafamostat mesylate in patients with end-stage renal failure can significantly improve the treatment effect and have high safety and clinical value.
We discuss the efficacy and safety of Nafamostat mesylate in patients with end-stage renal failure.